Evaluating treatment of hepatitis C for hemolytic anemia management

Swati DebRoy, Christopher Kribs-Zaleta, Anuj Mubayi, Gloriell M. Cardona-Meléndez, Liana Medina-Rios, MinJun Kang, Edgar Diaz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The combination therapy of antiviral peg-interferon and ribavirin has evolved as one of the better treatments for hepatitis C. In spite of its success in controlling hepatitis C infection, it has also been associated with treatment-related adverse side effects. The most common and life threatening among them is hemolytic anemia, necessitating dose reduction or therapy cessation. The presence of this side effect leads to a trade-off between continuing the treatment and exacerbating the side effects versus decreasing dosage to relieve severe side effects while allowing the disease to progress. The drug epoietin (epoetin) is often administered to stimulate the production of red blood cells (RBC) in the bone marrow, in order to allow treatment without anemia. This paper uses mathematical models to study the effect of combination therapy in light of anemia. In order to achieve this we introduce RBC concentration and amount of drug in the body as state variables in the usual immunological virus infection model. Analysis of this model provides a quantification of the amount of drug a body can tolerate without succumbing to hemolytic anemia. Indirect estimation of parameters allow us to calculate the necessary increment in RBC production to be ≥2.3 times the patient's original RBC production rate to sustain the entire course of treatment without encountering anemia in a sensitive patient.

Original languageEnglish (US)
Pages (from-to)141-155
Number of pages15
JournalMathematical Biosciences
Volume225
Issue number2
DOIs
StatePublished - Jun 2010

Fingerprint

hepatitis C
hemolytic anemia
Hemolytic Anemia
Hepatitis C
Red Blood Cells
Blood
erythrocytes
adverse effects
anemia
Therapy
Drugs
drugs
Erythrocytes
Pharmaceutical Preparations
Infection
Interferons
Anemia
therapeutics
Ribavirin
interferons

Keywords

  • Anemia
  • Epoietin
  • Hepatitis C
  • Interferon
  • Mathematical modeling
  • Ribavirin

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • Modeling and Simulation
  • Statistics and Probability
  • Applied Mathematics

Cite this

DebRoy, S., Kribs-Zaleta, C., Mubayi, A., Cardona-Meléndez, G. M., Medina-Rios, L., Kang, M., & Diaz, E. (2010). Evaluating treatment of hepatitis C for hemolytic anemia management. Mathematical Biosciences, 225(2), 141-155. https://doi.org/10.1016/j.mbs.2010.02.005

Evaluating treatment of hepatitis C for hemolytic anemia management. / DebRoy, Swati; Kribs-Zaleta, Christopher; Mubayi, Anuj; Cardona-Meléndez, Gloriell M.; Medina-Rios, Liana; Kang, MinJun; Diaz, Edgar.

In: Mathematical Biosciences, Vol. 225, No. 2, 06.2010, p. 141-155.

Research output: Contribution to journalArticle

DebRoy, S, Kribs-Zaleta, C, Mubayi, A, Cardona-Meléndez, GM, Medina-Rios, L, Kang, M & Diaz, E 2010, 'Evaluating treatment of hepatitis C for hemolytic anemia management', Mathematical Biosciences, vol. 225, no. 2, pp. 141-155. https://doi.org/10.1016/j.mbs.2010.02.005
DebRoy S, Kribs-Zaleta C, Mubayi A, Cardona-Meléndez GM, Medina-Rios L, Kang M et al. Evaluating treatment of hepatitis C for hemolytic anemia management. Mathematical Biosciences. 2010 Jun;225(2):141-155. https://doi.org/10.1016/j.mbs.2010.02.005
DebRoy, Swati ; Kribs-Zaleta, Christopher ; Mubayi, Anuj ; Cardona-Meléndez, Gloriell M. ; Medina-Rios, Liana ; Kang, MinJun ; Diaz, Edgar. / Evaluating treatment of hepatitis C for hemolytic anemia management. In: Mathematical Biosciences. 2010 ; Vol. 225, No. 2. pp. 141-155.
@article{8bb7cbda05904793bf3b24f65b60d3d0,
title = "Evaluating treatment of hepatitis C for hemolytic anemia management",
abstract = "The combination therapy of antiviral peg-interferon and ribavirin has evolved as one of the better treatments for hepatitis C. In spite of its success in controlling hepatitis C infection, it has also been associated with treatment-related adverse side effects. The most common and life threatening among them is hemolytic anemia, necessitating dose reduction or therapy cessation. The presence of this side effect leads to a trade-off between continuing the treatment and exacerbating the side effects versus decreasing dosage to relieve severe side effects while allowing the disease to progress. The drug epoietin (epoetin) is often administered to stimulate the production of red blood cells (RBC) in the bone marrow, in order to allow treatment without anemia. This paper uses mathematical models to study the effect of combination therapy in light of anemia. In order to achieve this we introduce RBC concentration and amount of drug in the body as state variables in the usual immunological virus infection model. Analysis of this model provides a quantification of the amount of drug a body can tolerate without succumbing to hemolytic anemia. Indirect estimation of parameters allow us to calculate the necessary increment in RBC production to be ≥2.3 times the patient's original RBC production rate to sustain the entire course of treatment without encountering anemia in a sensitive patient.",
keywords = "Anemia, Epoietin, Hepatitis C, Interferon, Mathematical modeling, Ribavirin",
author = "Swati DebRoy and Christopher Kribs-Zaleta and Anuj Mubayi and Cardona-Mel{\'e}ndez, {Gloriell M.} and Liana Medina-Rios and MinJun Kang and Edgar Diaz",
year = "2010",
month = "6",
doi = "10.1016/j.mbs.2010.02.005",
language = "English (US)",
volume = "225",
pages = "141--155",
journal = "Mathematical Biosciences",
issn = "0025-5564",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluating treatment of hepatitis C for hemolytic anemia management

AU - DebRoy, Swati

AU - Kribs-Zaleta, Christopher

AU - Mubayi, Anuj

AU - Cardona-Meléndez, Gloriell M.

AU - Medina-Rios, Liana

AU - Kang, MinJun

AU - Diaz, Edgar

PY - 2010/6

Y1 - 2010/6

N2 - The combination therapy of antiviral peg-interferon and ribavirin has evolved as one of the better treatments for hepatitis C. In spite of its success in controlling hepatitis C infection, it has also been associated with treatment-related adverse side effects. The most common and life threatening among them is hemolytic anemia, necessitating dose reduction or therapy cessation. The presence of this side effect leads to a trade-off between continuing the treatment and exacerbating the side effects versus decreasing dosage to relieve severe side effects while allowing the disease to progress. The drug epoietin (epoetin) is often administered to stimulate the production of red blood cells (RBC) in the bone marrow, in order to allow treatment without anemia. This paper uses mathematical models to study the effect of combination therapy in light of anemia. In order to achieve this we introduce RBC concentration and amount of drug in the body as state variables in the usual immunological virus infection model. Analysis of this model provides a quantification of the amount of drug a body can tolerate without succumbing to hemolytic anemia. Indirect estimation of parameters allow us to calculate the necessary increment in RBC production to be ≥2.3 times the patient's original RBC production rate to sustain the entire course of treatment without encountering anemia in a sensitive patient.

AB - The combination therapy of antiviral peg-interferon and ribavirin has evolved as one of the better treatments for hepatitis C. In spite of its success in controlling hepatitis C infection, it has also been associated with treatment-related adverse side effects. The most common and life threatening among them is hemolytic anemia, necessitating dose reduction or therapy cessation. The presence of this side effect leads to a trade-off between continuing the treatment and exacerbating the side effects versus decreasing dosage to relieve severe side effects while allowing the disease to progress. The drug epoietin (epoetin) is often administered to stimulate the production of red blood cells (RBC) in the bone marrow, in order to allow treatment without anemia. This paper uses mathematical models to study the effect of combination therapy in light of anemia. In order to achieve this we introduce RBC concentration and amount of drug in the body as state variables in the usual immunological virus infection model. Analysis of this model provides a quantification of the amount of drug a body can tolerate without succumbing to hemolytic anemia. Indirect estimation of parameters allow us to calculate the necessary increment in RBC production to be ≥2.3 times the patient's original RBC production rate to sustain the entire course of treatment without encountering anemia in a sensitive patient.

KW - Anemia

KW - Epoietin

KW - Hepatitis C

KW - Interferon

KW - Mathematical modeling

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=77952670173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952670173&partnerID=8YFLogxK

U2 - 10.1016/j.mbs.2010.02.005

DO - 10.1016/j.mbs.2010.02.005

M3 - Article

C2 - 20303990

AN - SCOPUS:77952670173

VL - 225

SP - 141

EP - 155

JO - Mathematical Biosciences

JF - Mathematical Biosciences

SN - 0025-5564

IS - 2

ER -